Sequenom Announces License And Marketing Agreements With Laboratoire Cerba In
SAN DIEGO and ST OUEN L'AUMONE, France, May 30, 2013
SAN DIEGO and ST OUEN L'AUMONE, France, May 30, 2013 /PRNewswire/ -- Sequenom,
Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic
analysis solutions, today announced that it, along with its wholly owned
subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), has entered
into technology licensing and marketing agreements with Laboratoire Cerba in
France for noninvasive prenatal aneuploidy testing. These agreements will
expand access to Sequenom CMM's MaterniT21™ PLUS laboratory-developed test and
the technology used in the test to healthcare providers and their patients via
Laboratoire Cerba's network in France, Belgium, Luxembourg and portions of the
Middle East and Africa.
"This new relationship with Laboratoire Cerba, one of the leading diagnostics
service providers in Europe, will enable us to leverage Laboratoire Cerba's
strong network of facilities to provide healthcare providers and their
patients with access to our innovative noninvasive prenatal testing (NIPT)
technology," said William Welch, President and COO, Sequenom, Inc. "We look
forward to collaborating with Cerba to continue to build upon the momentum
we've seen with the adoption of our testing services worldwide."
Under the terms of the license agreement, Sequenom will license its cell-free
fetal nucleic acid technology to Laboratoire Cerba to establish its
noninvasive fetal aneuploidy testing service in France. Laboratoire Cerba will
also have rights to market its noninvasive testing service in multiple
countries, including France, Luxembourg, Belgium, Lebanon, Morocco, Algeria,
Tunisia, Libya, Senegal, Ivory Coast, Burkina Faso and Cameroun. Effective
immediately, the contract term for the technology license is active through
"Combining Sequenom CMM's prenatal testing technology with our laboratory
testing expertise and network is great news for expectant families in Europe,
as we will be able to provide them important information about their
pregnancies in an accurate, safe and efficient method," said Sylvie CADO, COO,
Laboratoire Cerba. "We believe our markets are anxious for access to NIPT
technology, and we are enthusiastic to develop this innovative test in France.
This collaboration gives us the opportunity to increase our portfolio in the
field of noninvasive prenatal diagnosis. We look forward to a successful and
productive relationship with Sequenom and Sequenom CMM."
The MaterniT21 PLUS LDT analyzes the relative amount of 21, 18, 13, as well as
X and Y chromosomal material in cell-free DNA. The test is intended for use
in pregnant women at increased risk for fetal aneuploidy and can be used as
early as 10 weeks' gestation.Estimates suggest there are about 750,000
pregnancies at high risk for fetal aneuploidy each year in the United States.
The MaterniT21 PLUS test is available exclusively through the Sequenom CMM as
a testing service provided to physicians. To learn more about the test,
please visit www.Sequenomcmm.com.
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genetic analysis solutions.
Sequenom develops innovative technology, products and diagnostic tests that
target and serve discovery and clinical research, and molecular diagnostics
markets. The company was founded in 1994 and is headquartered in San Diego,
California. Sequenom maintains a Web site at http://www.sequenom.com to which
Sequenom regularly posts copies of its press releases as well as additional
information about Sequenom. Interested persons can subscribe on the Sequenom
Web site to email alerts or RSS feeds that are sent automatically when
Sequenom issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the Web site.
About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine (Sequenom CMM^®) is a CAP accredited
and CLIA-certified molecular diagnostics reference laboratory currently with
two locations dedicated to the development and commercialization of laboratory
developed tests for prenatal and eye conditions and diseases. Utilizing
innovative proprietary technologies, Sequenom CMM provides test results that
can be used by health care professionals in managing patient care. Testing
services are available only upon request by physicians. Sequenom CMM works
closely with key opinion leaders and experts in obstetrics, retinal care and
genetics. Sequenom CMM scientists use a variety of sophisticated and
cutting-edge methodologies in the development and validation of tests.
Sequenom CMM is changing the landscape in genetic diagnostics. Visit
http://www.sequenomcmm.com for more information on laboratory testing
SEQUENOM^®, MaterniT21™ and MaterniT21™ PLUS are trademarks of Sequenom, Inc.
All other trademarks and service marks are the property of their respective
About Laboratoire Cerba
Laboratoire Cerba is a leading European specialized laboratory based in France
and ISO 15189 accredited. Since its inception in 1967, it offers private
laboratories and public hospitals in more than 35 countries a broad range of
specialty testing services, such as molecular biology testing, oncology
testing, allergy testing, hormonology testing, infectious disease testing and
diagnostic genetic testing and has developed a broadly recognized expertise in
innovation for new tests.
It is the founding member of the Cerba European Lab Group, a leading European
clinical pathology laboratory, providing routine and specialized clinical
laboratory testing services primarily in France, Belgium and Luxembourg, and
supporting pharmaceutical and biotechnology companies worldwide in the
clinical trial phase of their drug development processes.
Through its Routine Lab and Specialized Testing operations, the Group offers a
range of over 2000 routine and specialty clinical tests used by doctors and
medical institutions to diagnose, monitor and treat diseases. The Central Lab
testing operations, which operated through the BARC subsidiaries, provide
safety and efficacy testing services to pharmaceutical companies and contact
research organizations worldwide in connection with drug development
For more information concerning CERBA, please consult our web site
Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding expectations for the
development and commercialization of prenatal laboratory testing services in
Europe, Africa and the Middle East, including laboratory developed tests for
fetal aneuploidies, the duration of and performance, sales and payment
expectations under the licensing agreement and marketing agreement, the
potential for additional launches in other countries, and Sequenom's
commitment to improving healthcare through revolutionary genetic analysis
solutions, are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and uncertainties that
may cause actual results to differ materially, including the risks and
uncertainties associated with reliance upon the collaborative efforts of
Laboratoire Cerba, Sequenom, and Sequenom CMM and those parties' abilities to
develop and commercialize new technologies and products, particularly new
technologies such as prenatal and other diagnostics and laboratory developed
tests, Sequenom's ability to manage its existing cash resources or raise
additional cash resources, competition, intellectual property protection and
intellectual property rights of others, government regulation particularly
with respect to diagnostic products and laboratory developed tests, obtaining
or maintaining regulatory approvals, ongoing litigation and investigations and
other risks detailed from time to time in Sequenom, Inc.'s most recent Annual
Report on Form 10-K and other documents subsequently filed with or furnished
to the Securities and Exchange Commission. These forward-looking statements
are based on current information that may change and you are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date of this press release. All forward-looking statements are
qualified in their entirety by this cautionary statement, and Sequenom, Inc.
undertakes no obligation to revise or update any forward-looking statement to
reflect events or circumstances after the issuance of this press release.
SOURCE Sequenom, Inc.
Contact: Sequenom: Marcy Graham, Senior Director, Investor Relations & Corp
Comm, Sequenom, Inc., 858-202-9028, firstname.lastname@example.org, and Jakob Jakobsen,
Media Contact, Chandler Chicco Agency, 310-309-1003,
email@example.com, or Laboratoire CERBA: Pascale Laurent,
Communication Director, +33 1 34 40 21 63, firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.